Marietta Solomon
Family Medicine · Bonifay, FLNPI 1407416951
Payments from drug & device makers
Across 107 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$447
- AstraZeneca$193
- GSK$184
- Lilly USA, LLC$140
- Novo Nordisk$120
- Bayer$83
- plus $505 from 18 others
What the payments were for
- Food & beverage$1,672100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $447 |
| AstraZeneca | 11 | $193 |
| GSK | 12 | $184 |
| Lilly USA, LLC | 10 | $140 |
| Novo Nordisk | 6 | $120 |
| Bayer | 4 | $83 |
| Novartis | 6 | $79 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Nevro Corp. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $35 |
| Esperion Therapeutics, Inc. | 1 | $32 |
| Amgen | 2 | $26 |
| Eisai Inc. | 2 | $26 |
| Vertex | 1 | $24 |
| Dexcom, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Exact Sciences | 1 | $14 |
| Scynexis, Inc. | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Inogen, Inc. | 1 | $7 |
How this compares
$1,672 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 123 | $183,374 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $103,489 |
| FarxigaDapagliflozin Propanediol | 50 | $60,182 |
| OzempicSemaglutide | 29 | $50,820 |
| XareltoRivaroxaban | 46 | $48,541 |
| JardianceEmpagliflozin | 41 | $42,869 |
| EliquisApixaban | 40 | $42,420 |
| JanuviaSitagliptin Phosphate | 24 | $26,514 |
| EntrestoSacubitril/Valsartan | 13 | $17,694 |
| LinzessLinaclotide | 11 | $15,837 |
| MyrbetriqMirabegron | 19 | $14,282 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $12,036 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $10,824 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $6,343 |
| Gabapentin | 162 | $3,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $140 | $183,374123 claims |
| GSKTrelegy Ellipta | $184 | $103,48997 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $193 | $72,21863 claims |
| Novo NordiskOzempic | $120 | $50,82029 claims |
| Johnson & JohnsonXarelto | $35 | $48,54146 claims |
| NovartisEntresto | $79 | $17,69413 claims |
| AbbVieLinzess | $447 | $15,83711 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $14,28219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Bonifay
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.